Arbutus Biopharma Corporation (NasdaqGS: ABUS)
Health Care · Biotechnology · US
$5.20
-0.19% today · +48.6% 1Y
Arbutus Biopharma Corporation (NasdaqGS: ABUS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.03B and employs 19 people.
Over the last twelve months the share price has gained 48.6%, trading between 3.49 and 5.45.
Tweenvest scores Arbutus Biopharma Corporation across four factors: quality 39/100, value 36/100, growth 69/100. Its strongest factor is growth.
ABUS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.03B
- Revenue (TTM)
- $181.72M
- P/E
- 6.59
- EPS
- 0.79
- Dividend yield
- —
- Beta (5Y)
- 0.60
- 52-week high
- $5.45
- 52-week low
- $3.49
- Avg volume (3M)
- —
- Shares outstanding
- 197.85M
- Employees
- 19
- Next earnings
- —
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
- ISIN
- CA03879J1003
- Founded
- 2005
- Listed since
- Jul 26, 2007
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.